Abstract: Anti-platelet therapy is an ongoing topic in the field of cardiovascular medicine. Worldwide scholars are trying to find a balance between bleeding and thrombosis. The search for new anti-platelet drugs continues. At present, dual anti-platelet therapy of aspirin and clopidogrel is the standard treatment for patients with acute coronary syndrome. In recent years, the emergence of new P2Y12 receptor blockers challenges the standard scheme. In this article, the mechanism and clinical characteristics of anti-platelet effects of various P2Y12 receptor blockers are reviewed, providing a theoretical basis for the clinical application and further research of P2Y12 receptor blockers.